Jirui Pharmaceutical

G-ray Pharma is a clinical-stage biotechnology company specializing in the development of next-generation radiopharmaceuticals, with a core focus on Targeted Alpha Therapy (TAT). Founded in 2021 and headquartered in Suzhou, China, the company leverages alpha-emitting isotopes such as Actinium-225 to deliver high-energy radiation with extreme precision to cancer cells. Its lead program, GR01, is a PSMA-targeted radiotherapeutic currently in Phase 1 clinical trials for the treatment of metastatic castration-resistant prostate cancer. G-ray Pharma's integrated platform encompasses ligand discovery, chelator technology, and specialized manufacturing capabilities for nuclear medicine. The company has successfully raised significant capital from top-tier investors including Sequoia China and GL Capital to advance its pipeline of innovative oncology treatments.